# Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

> **NCT05096039** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1614719 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Sacubitril/valsartan
- **DRUG:** ACEI or ARB and no sacubitril/valsartan

## Key facts

- **NCT ID:** NCT05096039
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-10
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 1614719 (ACTUAL)
- **Last updated:** 2021-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096039, "Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05096039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*